Free Download

Volume: 0 - Issue: 0

First page: 0 - Last page: 0

S. Uyttebroek - C. Claeyssens - M. Jorissen - L. Dupont - L. Van Gerven

Background: The introduction of CFTR modulators has changed the landscape in the treatment of cystic fibrosis (CF) and early
case series have shown improvements in sinonasal outcomes in this patient population.
Methodology: A real-word data study was performed to evaluate the impact of dual therapy with tezacaftor/ivacaftor (TEZ/IVA)
and triple therapy with elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on CF-related chronic rhinosinusitis (CRS), by comparing
subjective and objective outcome measures at baseline, 12 months after treatment with TEZ/IVA and six months after treatment
with ELX/TEZ/IVA.
Results: In total, 43 CF patients, with a mean age of 32 years, were included. After triple therapy, significant improvements in
overall visual analogue scale, SNOT-22, Lund Kennedy, nasal polyps, and Lund-Mackay scores were observed, whereas no beneficial
effect could be seen in patients treated with dual therapy. Bacterial upper airway colonization did not differ pre- and postmodulator
therapy in the present study. The number of responders to dual and triple therapy is 23.8% and 63.2% of the patients,
respectively.
Conclusions: Triple therapy with ELX/TEZ/IVA is superior to dual therapy with TEZ/IVA in the treatment of CF-CRS, as significantly
reduced sinonasal complaints, nasal endoscopy and CT scores were observed after triple therapy, whereas this was not the case
for dual therapy.

Rhinology 0-0: 0-0, 0000